EA202090939A1 - MODULATION OF THE IMMUNE RESPONSE USING ANTI-BODY-DRUG CONJUGATES - Google Patents

MODULATION OF THE IMMUNE RESPONSE USING ANTI-BODY-DRUG CONJUGATES

Info

Publication number
EA202090939A1
EA202090939A1 EA202090939A EA202090939A EA202090939A1 EA 202090939 A1 EA202090939 A1 EA 202090939A1 EA 202090939 A EA202090939 A EA 202090939A EA 202090939 A EA202090939 A EA 202090939A EA 202090939 A1 EA202090939 A1 EA 202090939A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immune response
drug conjugates
modulation
cells
regulatory
Prior art date
Application number
EA202090939A
Other languages
Russian (ru)
Inventor
Райан Хейзер
Шира Гардай
Дэвид Тафт
Кэрол Энн Огден
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Priority claimed from PCT/US2018/055388 external-priority patent/WO2019075188A1/en
Publication of EA202090939A1 publication Critical patent/EA202090939A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к способам и композициям для модуляции иммунного ответа у субъекта, такой как уменьшение активности CD30регуляторных T-клеток и увеличение отношения CD8T-клеток к CD30регуляторным T-клеткам путем введения конъюгатов антитело-лекарственное средство, которые связываются с CD30. Изобретение также относится к готовым изделиям или наборам, содержащим указанные конъюгаты антитело-лекарственное средство, которые связываются с CD30, для модуляции иммунного ответа.The invention provides methods and compositions for modulating an immune response in a subject, such as decreasing the activity of CD30 regulatory T cells and increasing the ratio of CD8T cells to CD30 regulatory T cells by administering antibody-drug conjugates that bind to CD30. The invention also relates to finished articles or kits containing said antibody-drug conjugates that bind to CD30 to modulate an immune response.

EA202090939A 2018-04-13 2018-10-11 MODULATION OF THE IMMUNE RESPONSE USING ANTI-BODY-DRUG CONJUGATES EA202090939A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862657511P 2018-04-13 2018-04-13
PCT/US2018/055388 WO2019075188A1 (en) 2017-10-13 2018-10-11 Modulating the immune response using antibody-drug conjugates

Publications (1)

Publication Number Publication Date
EA202090939A1 true EA202090939A1 (en) 2020-07-20

Family

ID=71833515

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090939A EA202090939A1 (en) 2018-04-13 2018-10-11 MODULATION OF THE IMMUNE RESPONSE USING ANTI-BODY-DRUG CONJUGATES

Country Status (1)

Country Link
EA (1) EA202090939A1 (en)

Similar Documents

Publication Publication Date Title
EA201792451A1 (en) ANTIBODIES TO OX40 AND METHODS OF THEIR APPLICATION
GEP20227419B (en) Pd-1-binding molecules and methods of use thereof
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
MX2021003435A (en) Collagen-localized immunomodulatory molecules and methods thereof.
EA201892362A1 (en) AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS
EA201891983A8 (en) COMBINED THERAPY BY ANTIBODIES TO CD73
EA201891992A1 (en) CHIMERIC RECEPTORS AND WAYS OF THEIR APPLICATION
MD3880654T2 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
AR114283A1 (en) DLL3 CHEMERIC RECEPTORS AND METHODS FOR THEIR USE
EA201791782A1 (en) 4,6-DIAMINOPIRIDO [3,2-D] Pyrimidine COMPOUNDS MODULATING TOLL-SIMILAR RECEPTORS
EA202190609A1 (en) ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G
EA201692458A1 (en) ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION
EA202090296A1 (en) SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PREPARATION AND APPLICATION
EA201791270A1 (en) MODIFIED APRIL-BINDING ANTIBODIES
EA201991600A1 (en) COMPOUNDS MODULATING THE Aryl Hydrocarbon Receptor (AhR)
EA201991546A1 (en) ANTIGEN-BINDING PROTEINS AGAINST NEUROPILIN AND WAYS OF THEIR APPLICATION
WO2019094595A3 (en) Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
EA202191175A1 (en) CYSTEINE-DESIGNED ANTIBODY-DRUG CONJUGATES CONTAINING PEPTIDE-CONTAINING LINKERS
EA201892225A1 (en) ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION
BR112022012410A2 (en) SMARCA DEGRADATORS AND USE THEREOF
EA202190304A1 (en) CHIMERIC RECEPTORS TO STEAP1 AND METHODS FOR THEIR APPLICATION
MX2020005555A (en) Tau peptide immunogen constructs.
EA201990978A1 (en) ANTIBODIES AGAINST PD-1
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof